April edition of Australian Prescriber out now

Vaccination and antivirals: the tools of flu prevention and treatment

Infectious diseases physician Dr Nicole Gilroy and co-authors examine the role of vaccines and antiviral medicines in preventing or treating influenza. Vaccination is the primary defence against influenza. Antivirals can reduce symptom duration by about a day. They are also used as a prophylaxis in high-risk populations.

Drug-induced movement disorders

Many therapeutic and illicit drugs can cause movement disorders, with symptoms including tremors, irregular movements and stiffness. Drs Stephen Duma and Victor Fung detail drug-induced movement disorders ranging from acute disorders with symptoms starting directly after taking the drug, through to tardive disorders which occur either during exposure or within weeks of stopping a drug. Treatment includes stopping the offending drug, supportive care and sometimes other pharmacological treatment.

Reviving the body's immune response against tumours in hiding

Immune checkpoint inhibitors enable the body's immune system to recognise and kill tumour cells that have adapted to escape detection. Medical oncology advanced trainee Luke Ardolino gives an overview of how these treatments work against a range of cancers, and how their efficacy compares with standard chemotherapy. While checkpoint inhibitors have significant benefits over conventional therapies, immune-related adverse effects such as pneumonitis, hepatitis and nephritis present clinicians with a new challenge of recognising them early and acting promptly.

Other articles in the April issue of Australian Prescriber include:

- My Health Record: a community pharmacy perspective

- Real-time prescription monitoring: lessons from Tasmania

- New drugs: Bictegravir/emtricitabine/tenofovir alafenamide for HIV infection, ertugliflozin for type 2 diabetes, midostaurin for acute myeloid leukaemia, mastocytosis and mast cell leukaemia, nusinersen for spinal muscular atrophy, pralatrexate for lymphoma, safinamide for Parkinson's disease.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).